Themis Medicare Ltd
Themis Medicare Q3 FY24 earnings call: Revenue & Margins
Q3 FY24 investor presentation: what the company reported on revenue, margins and capex.
- Revenue
- ₹83Cr
- Net profit
- ₹7Cr
- Margin
- 9.76%
Top 10 Pharmaceuticals & Biotechnology companies on management guidance
See the sector's top 10 — free with your mobile number.
Based on Themis Medicare Ltd's Q3 FY24 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q3 FY24 Net Revenue: Rs. 82.51 Cr, down 7.06% year-on-year from Rs. 88.78 Cr in Q3 FY23 (Page 8). Q3 FY24 Financials:.
From Themis Medicare Ltd's Q3 FY24 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Q3 FY24 Net Revenue: Rs. 82.51 Cr, down 7.06% year-on-year from Rs. 88.78 Cr in Q3 FY23 (Page 8).
- Hospital Business grew by 19% year-on-year for 9M FY24 (Page 8, Page 6).
- 9M FY24 Net Revenue: Rs. 283.94 Cr, up 3.55% year-on-year from Rs. 274.22 Cr in 9M FY23 (Page 9).
2 more points from Themis Medicare Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Themis Medicare Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
2 more points from Themis Medicare Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Themis Medicare Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Themis Medicare Ltd said on order book & pipeline — free account, 30 seconds.
Themis Medicare Ltd — Quarterly revenue & net profit
Themis Medicare Ltd Q3 FY24 results — key figures
| ₹ Cr | Q3 FY24 | Q2 FY24 | QoQ |
|---|---|---|---|
| Revenue | 83 | 105 | -21.3% |
| Operating profit (EBITDA) | 8 | 12 | -35.1% |
| Operating margin | 9.76% | 11.84% | -2.1 pp |
| Profit before tax | 8 | 14 | -41.2% |
| Net profit (PAT) | 7 | 11 | -34.9% |
| EPS (₹) | 0.80 | 1.23 | -35% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹77 Cr, net profit ₹9 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Themis Medicare's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Wockhardt (Q3 FY24)
Net Sales Revenues for 9M FY24: INR 2,129 Cr. Key concall takeaways from Wockhardt Ltd's Q3 FY24 earnings call — and how it ranks against sector peers.
- NGL Fine Chem (Q3 FY24)
Q3FY24 Revenue from Operations: ₹87.95 crore, up 22.27% year-on-year (YoY) from Q3FY23 ₹71.93 crore (Page 8). Key concall takeaways from NGL Fine Chem Ltd's Q3…
- Anuh Pharma (Q3 FY24)
172.10 Cr, a 15% increase quarter-on-quarter and 31% year-on-year over 9M FY23. Key concall takeaways from Anuh Pharma Ltd's Q3 FY24 earnings call — and how it…
- Bharat Parenterals (Q3 FY24)
Revenue from operations: ₹58.8 crore (down 0.4% YoY) . Key concall takeaways from Bharat Parenterals Ltd's Q3 FY24 earnings call — and how it ranks against…
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Themis Medicare Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Themis Medicare Ltd Q3 FY24 results?
Q3 FY24 Net Revenue: Rs. 82.51 Cr, down 7.06% year-on-year from Rs. 88.78 Cr in Q3 FY23 (Page 8). Q3 FY24 Financials:.
What is Themis Medicare Ltd share price analysis?
Themis Medicare Ltd currently shows a neutral. The stock trades at a P/E of N/A with a market cap of ₹1,142 Cr. Investors should review the full earnings analysis for detailed insights.
Keep Themis Medicare Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.